Trial Profile
Randomized, Multinational, Multicenter, Double-Blind, Placebo-Controlled, Two-Arm Parallel Group Trial of Rimonabant 20 mg OD for Reducing the Risk of Major Cardiovascular Events in Abdominally Obese Patients With Clustering Risk Factors
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 20 Jan 2022
Price :
$35
*
At a glance
- Drugs Rimonabant (Primary)
- Indications Cardiovascular disorders; Obesity
- Focus Therapeutic Use
- Acronyms CRESCENDO
- Sponsors Sanofi; Sanofi-Synthelabo
- 19 Jan 2022 This trial has been completed in Greece (End Date: 29 Apr 2009), according to European Clinical Trials Database record.
- 19 Oct 2012 Planned number of patients changed from 18695 to 20300.
- 14 Aug 2010 The CRESCENDO study was discontinued early due to concerns by health regulatory authorities about suicide in patients receiving rimonabant.